Get started
Author

Marinha Costa Rivas

Observed names: M. C. Rivas, M. Costa Rivas
Institution: Povisa Hospital
ORCID: 0000-0002-9566-9561
Observed ORCID: 0000-0002-9566-9561
OpenAlex ID: A5056273574
Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.
2018 · Mariano Provencio-Pulla, Ernest Nadal-Alforja, et al. · Journal of Clinical Oncology · 69
Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence
2022 · Paula Jiménez-Fonseca, Enrique Gallardo, et al. · European Journal of Internal Medicine · 20
PDF
Decrease in Circulating Tumor Cells as an Early Marker of Therapy Effectiveness
2001 · J.-C. Bystryn, J. Albrecht, et al. · Recent results in cancer research/Recent Results in Cancer Research · 7
Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group
2018 · M. Costa Rivas, G. Huidobro Vence, et al. · Clinical & Translational Oncology · 3
Analysis of the relationship between ratio N/L and survival in lung cancer patients treated with immunotherapy.
2019 · Noemi De Dios Alvarez, Marinha Costa Rivas, et al. · Journal of Clinical Oncology · 1
Vall d’Hebron Institute of Oncology (VHIO) immuno-oncology prognostic index (VIO): A new tool for improved patient (pt) selection in phase I (Ph1) trials with immune checkpoint inhibitors (ICI)
2018 · C. Hierro, I. Matos, et al. · Annals of Oncology · 1
Prognostic value of systemic inflammation markers in advanced esophageal squamous cell carcinoma treated with second-line nivolumab: a real-world European study
2026 · Nieves Martínez-Lago, Paula González Villarroel, et al. · Scientific Reports
PDF
PB0980 TINzaparin PROphylaxis in Patients with Metastatic COLorectal Cancer (PROTINCOL)
2023 · A. Muñoz Martín, J. de la Cámara Gómez, et al. · Research and Practice in Thrombosis and Haemostasis
P-277 Real-world efficacy, safety, and impact of the GIPI score of nivolumab in advanced esophageal squamous cell carcinoma (ESCC) refractory or intolerant to prior chemotherapy in European population: The EPIC trial
2023 · N. Martínez Lago, A. Cousillas Castiñeiras, et al. · Annals of Oncology
PDF
Real-world outcomes for patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with nivolumab: A Galician multicentric study (Spain).
2021 · Leticia Iglesias Rey, Rocio Vilchez Simo, et al. · Journal of Clinical Oncology
Analysis of the relationship between heading N / L and survival in patients treated with immunotherapy in lung cancer
2018 · N. De Dios Alvare, M. Costa Rivas, et al. · Annals of Oncology
Concurrent chemoradiation (CChRT) for locally advanced stage III non-small cell lung cancer (NSCLC) with cisplatin and vinorelbine and thoracic radiotherapy: A phase II study from the Galician Lung Cancer Group.
2017 · Susana Gomez Garcia, Marinha Costa Rivas, et al. · Journal of Clinical Oncology
ERCC1 expression in tumor tissue as biomarker of outcomes of oral vinorelbine-cisplatin (oVP) combination in metastatic squamous cell lung cancer (SqLC): A prospective study—GGCP 052/12.
2016 · Carolina Pena, Monica Alvarez, et al. · Journal of Clinical Oncology
Works count: 13
Citation count: 101
H-index: 3
I10-index: 2
Year
Topic
Type